PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announced that it has reported its unaudited interim financial results for the three and nine month period ended September 30, 2022.

Third Quarter 2022 Financial Results

A copy of the unaudited condensed consolidated interim financial statements prepared in accordance with International Financial Reporting Standards and the corresponding management’s discussion and analysis for the three and nine months ended September 30, 2022, can be found under PsyBio’s profile on SEDAR at www.sedar.com.

Intellectual Property and Clinical Development Milestones

  • The Company recently announced that it has reached an initial agreement with experienced clinical researchers to conduct a clinical trial utilizing PsyBio’s proprietary biosynthetic psilocybin product upon obtaining all necessary approvals and licenses.
  • The Company recently announced the formal acceptance by the United States Patent and Trademark Office of its latest U.S. PCT (Non-Provisional) Patent Application.
  • The Company plans to communicate additional patent filings and conversions before the end of 2022, and expects to bring its total US Patent Applications to twenty nine, US Provisional Applications to nineteen, and US PCT Non-provisional Applications to ten. 

About PsyBio Therapeutics Corp

PsyBio Therapeutics is an intellectual property driven biotechnology company developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof.  The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.